187 related articles for article (PubMed ID: 38496070)
1. A Comparative Study of the Safety and Efficacy Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on the Management of Hypertension: A Systematic Review.
Peresuodei TS; Gill A; Orji C; Reghefaoui M; Saavedra Palacios MS; Nath TS
Cureus; 2024 Feb; 16(2):e54311. PubMed ID: 38496070
[TBL] [Abstract][Full Text] [Related]
2. Updates on the treatment of essential hypertension: a summary of AHRQ's comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors.
Powers B; Greene L; Balfe LM
J Manag Care Pharm; 2011 Oct; 17(8 Suppl):S1-14. PubMed ID: 22088101
[TBL] [Abstract][Full Text] [Related]
3. The Divergent Cardiovascular Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Myocardial Infarction and Death.
Strauss MH; Hall AS
Prog Cardiovasc Dis; 2016; 58(5):473-82. PubMed ID: 26586276
[TBL] [Abstract][Full Text] [Related]
4. Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis.
Batty JA; Tang M; Hall M; Ferrari R; Strauss MH; Hall AS
Syst Rev; 2018 Aug; 7(1):131. PubMed ID: 30144828
[TBL] [Abstract][Full Text] [Related]
5. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
[TBL] [Abstract][Full Text] [Related]
6. Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy.
Neutel JM
Curr Med Res Opin; 2010 Jan; 26(1):213-22. PubMed ID: 19921961
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults.
Dorosch T; Ganzer CA; Lin M; Seifan A
Curr Pain Headache Rep; 2019 Sep; 23(11):85. PubMed ID: 31515634
[TBL] [Abstract][Full Text] [Related]
8. EVALUATING THE PRESCRIPTION OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR RECEPTOR BLOCKERS IN PATIENTS WITH DIABETES IN JORDAN.
Mayyas F; Bataineh W; Jarab A
Endocr Pract; 2017 Nov; 23(11):1289-1296. PubMed ID: 28816537
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients.
Zhang L; Zeng X; Fu P; Wu HM
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD009120. PubMed ID: 24953826
[TBL] [Abstract][Full Text] [Related]
10. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers in hypertensive patients with myocardial infarction or heart failure: a systematic review and meta-analysis.
Ohtsubo T; Shibata R; Kai H; Okamoto R; Kumagai E; Kawano H; Fujiwara A; Kitazono T; Murohara T; Arima H
Hypertens Res; 2019 May; 42(5):641-649. PubMed ID: 30948834
[TBL] [Abstract][Full Text] [Related]
12. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
[TBL] [Abstract][Full Text] [Related]
13. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management.
Petrella R; Michailidis P
Clin Ther; 2011 Sep; 33(9):1190-203. PubMed ID: 21885126
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
Lee J; Lee S
Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in diabetic nephropathy: a systematic review and meta-analysis.
Du YH; Guan CJ; Li LY; Gan P
Ann Palliat Med; 2022 Mar; 11(3):1093-1101. PubMed ID: 35365039
[TBL] [Abstract][Full Text] [Related]
17. The divergent protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on clinical outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.
Xie Q; Tang S; Li Y
Ann Palliat Med; 2022 Apr; 11(4):1253-1263. PubMed ID: 34775774
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
19. Renin-angiotensin-aldosterone system blockers and cardiovascular outcomes: a meta-analysis of randomized clinical trials.
Kızılırmak P; Üresin Y; Özdemir O; Kılıçkıran Avcı B; Tokgözoğlu L; Öngen Z
Turk Kardiyol Dern Ars; 2017 Jan; 45(1):49-66. PubMed ID: 28106020
[TBL] [Abstract][Full Text] [Related]
20. Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.
Ferrario CM
Life Sci; 2010 Feb; 86(9-10):289-99. PubMed ID: 19958778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
